Pharma BD Deal Intelligence
The 1989 $16B merger of Bristol-Myers and Squibb Corporation that created one of pharma's most enduring franchises. The combined entity built leadership in cardiovascular, oncology, and immunology—eventually acquiring Celgene for $74B and dominating hematologic malignancies.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Bristol-Myers Company and Squibb Corporation announced a stock-for-stock merger of equals on July 27, 1989 valued at approximately $12-16 billion, closing October 4, 1989 to form Bristol-Myers Squibb Company. At the time, it was the largest pharmaceutical merger in US history and created one of the largest healthcare companies globally, with combined revenues of ~$8.9 billion. Bristol-Myers contributed a diversified portfolio across pharmaceuticals (Cefzil, Buspar), consumer health (Bufferin, Excedrin), Mead Johnson infant nutrition, and Clairol hair care. Squibb brought cardiovascular leadership anchored by Capoten (captopril — the first ACE inhibitor, ~$1.6B peak sales) and Monopril (fosinopril), plus oncology assets including early-stage paclitaxel (later launched as Taxol). Richard Gelb (ex-Bristol-Myers) served as chairman; Richard Furlaud (ex-Squibb) as vice-chairman. The merger pioneered the modern large-pharma consolidation era, preceding SmithKline/Beecham (1989), Glaxo/Burroughs Wellcome (1995), and the broader 1990s-2000s M&A wave.
18M US cases/yr · $12.0B US Cardiovascular Rx Market (1989)
The 1989 merger of Bristol-Myers and Squibb for $12B created a cardiovascular powerhouse anchored by Pravachol (pravastatin) for hyperlipidemia and Monopril (fosinopril) for hypertension, complementing Bristol-Myers existing consumer health and OTC strengths with Squibb prescription drug expertise.
Pravachol became a leading statin with peak sales exceeding $2.9B, while Monopril generated $380M annually. The combined entity leveraged Squibb cardiovascular R&D to build a pipeline that later yielded Plavix (co-marketed with Sanofi) and positioned BMS as a cardiovascular leader through the 1990s.
1M US cases/yr · $3.5B US Oncology Rx Market (1989)
BMS became a major oncology player post-merger through Taxol (paclitaxel), approved for ovarian cancer in 1992 and breast cancer in 1994, and Paraplatin (carboplatin) for ovarian cancer combination therapy. These cytotoxic agents established BMS as a leading oncology franchise well before the targeted therapy era.
Taxol became one of the best-selling cancer drugs of the 1990s with peak sales of $1.6B. BMS later expanded into targeted oncology through acquisitions, eventually building the immuno-oncology franchise anchored by Opdivo (nivolumab) decades later.
Bristol-Myers and Squibb completed $12B stock swap forming world second-largest pharma company.
Combined 1988 revenue $8.6B and profits $1.3B, diversified pharma-consumer health powerhouse.
Merged Bristol-Myers consumer/OTC marketing with Squibb prescription drug expertise.
BMS grew into top-5 global pharma with major cardiovascular, oncology, immunology franchises.
1989 merger created BMS, one of world most innovative pharma companies. Complementary capabilities produced decades of value.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Company / Squibb Corporation (this deal) | 1989 | $16.0B | 83 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Astra AB / Zeneca Group plc | 1998 | $35.0B | 94 |
| Merck & Co. Inc. / Acceleron Pharma Inc. | 2021 | $11.5B | 90 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
← Browse all deals · How we score deals
More: 1989 deals · Cardiovascular deals